Leuchtturmprojekt Forschungscampus BioMedTech Teilprojekt 2

Project Image:
Title of the project:
Leuchtturmprojekt Forschungscampus BioMedTech Teilprojekt 2
RegioWIN Leuchtturmprojekt LTP3: Forschungscampus BioMedTech, Project 2: Verbund BioMedTech: System immunology at biological-technical interfaces
Cooperation between science and industry at the interface of bio- and material sciences.
Project leader:
Dr. Thomas Joos
Project funding:
  • Europäische Fonds für regionale Entwicklung EFRE (50%)
  • Ministerium für Wirtschaft, Arbeit und Wohnungsbau (- 20%)
Funding reference number:

The BioMedTech research campus is located in the Technology Park Tübingen-Reutlingen, in the immediate vicinity of the NMI. It will provide space for cooperation between science and industry at the interface of the bio- and material sciences.


The campus units thematically and spatially two sectors of medical technology and biotechnology. Regional medical technology and biotechnology companies and basic and applied research institutions will work together here. In this way, research projects for medicine of the future can be translated into internationally marketable and competitive products and processes. At the same time, the Leuchtturmprojekt is investing in an initial collaborative research project. Under the project title "system immunology at biological-technical interfaces", immune reactions that can occur in contact with technical interfaces and materials, such as implants, blood tubes or blood filters, are being researched. The common vision of scientists and research-based companies on the research campus is to be able to predict the immunological reactivities of a wide variety of materials, material surfaces and material structures. Inflammations, rejections, sensitizations and Allergies are severe immune reactions among which many patients
suffer from contact with technical interfaces and materials. In connection with pre-existing diseases, different metabolic situations and genetic dispositions, these undesired reactions can vary from patient to patient. Under the leadership of the NMI, scientists from the University of Tübingen and Reutlingen University of Applied Sciences, together with three regional companies, are investigating the connections that lead to these immunological reactions.

Project partners:
  • CeGaT GmbH Tübingen
  • Eberhard-Karls-Universtiät Tübingen
  • Hochschule Reutlingen
  • Hot Screen GmbH, Reutlingen
  • Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH, Reutlingen
  • Universtiätsklinkium Tübingen